China Medical Technologies Announces the Recent Publication of a Study on its SPR Analyzer and HPV DNA Chip in Cancer Genetics and Cytogenetics and the Creation of a Medical Publications Column to the Investor Relations Section on its Website

BEIJING, June 29 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced the recent publication of a large sample study on the Company's SPR analyzer and related HPV DNA chip (the "SPR System") for the detection of 16 high risk and 8 low risk genotypes of human papillomavirus ("HPV"). The study tested specimens of 560 patients with atypical squamous cells of undetermined significance ("ASCUS") or above using the SPR System and compared the results with sequence analysis. The study concluded that the SPR System is highly sensitive and specific in HPV genotyping (99% concordance between the SPR System and sequence analysis) and can become an effective approach for HPV genotyping in a clinical setting.

The study is entitled, "A Surface Plasmon Resonance-based System to Genotype Human Papillomavirus", and can be found in the online edition of the medical journal Cancer Genetics and Cytogenetics, Volume 200, Issue 2, at http://cancergeneticsjournal.org .

The Company also announced the creation of a new column "Medical Publications" in its investor relations section at http://ir.chinameditech.com which currently posts 12 articles from Chinese medical publications. The articles related to the use of the Company's FISH products in various applications including prenatal diagnosis, cancer detection and companion diagnostic for targeted cancer drugs. The Company plans to update the column periodically to add medical publications related to the Company's products following approval from the authors.

About China Medical Technologies, Inc.

China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales force and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com .

For more information, please contact:

Winnie Yam

Tel: +852-2511-9808

Email: IR@chinameditech.com